Ribociclib

Status:
Red
Decision Date:
January 2018
 

Comments

RED1,2,3,8: NICE TA496 - for use in combination with an aromatase inhibitor for previously untreated hormone receptor-positive, HER2 negative, locally advanced or metastatic breast cancer. 

RED1,2,3,8: NICE TA593 - treating hormone receptor-positive, HER2-negative, advanced breast cancer (Decision date - September 2019)

RED1,2,3,8: NICE TA687 - with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer. Replaces NICE TA593 (Decision date - April 2021)


Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app